Overview

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Status:
Completed

Trial end date:
2019-08-25

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety of ifosfamide when added to the combination regimen of olaratumab and doxorubicin in participants with advanced or metastatic soft tissue sarcoma (STS).

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Doxorubicin
Ifosfamide
Isophosphamide mustard
Liposomal doxorubicin
Mesna
Olaratumab